四环医药(00460)午后涨超9%，截至发稿，涨6.25%，报0.68港元，成交额3887.85万港元。

消息面上，四环医药拟于3月28日举行董事会会议审批年度业绩。公司此前发布业绩预告称，预期2024年录得不低于人民币18亿元的收入及不超过人民币6亿元的亏损。值得注意的是，集团的医美业务延续2024年上半年的走势，保持了不低于50%的高速增长。

智通财经在《百亿CDK4/6市场变天，四环医药（00460）吡洛西利凭“双优“数据挑战三巨头》中指出，近期，徐兵河院士团队发表在《Cancer Communications》的BRIGHT-1研究数据显示，吡洛西利在HR+/HER2-晚期乳腺癌后线治疗中展现出“超能打”的临床实力。不管是有效性，安全性，还是长期服药耐受性，都有惊艳表现。四环医药旗下轩竹生物的核心产品吡洛西利凭借突破性临床数据，有望成为国内首个单药后线治疗HR+/HER2-局部晚期或转移性乳腺癌的CDK4/6抑制剂，重塑晚期乳腺癌的治疗范式。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.